| Name | Title | Contact Details |
|---|---|---|
Ryan Lockard |
VP, Infra & Platform Engineering (Healthcare Delivery) | Profile |
Shane Henderson |
Chief Technology Officer and Chief Digital Officer | Profile |
Mark Magpayo |
Director, Security Operations | Profile |
Sonia Arista |
Senior Vice President - Chief Information Security Officer | Profile |
Joshua Builder |
Chief Technology Officer and Executive Vice President of Clinical Operations | Profile |
Lawnwood Regional Medical Center and Heart Institute is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedRisk is the leading provider of managed physical medicine for the workers` compensation industry and related market sectors. Unified through a uniquely integrated, US-based support model, we pride ourselves in combining clinical expertise with highly personal service and responsiveness. This focus allows us to offer distinct value to each stakeholder in the workers` comp process – carriers and TPAs, employers, adjusters and case managers, physicians, network providers and the patients themselves. In short, we`re here for you; at MedRisk, you`re never just a number – you`re an individual who deserves a solution tailored to your exact needs. We`re here to help you reach your goals and improve your outcomes – whatever they may be.
Virginia Hospital is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
AMAR INTERNATIONAL is a Fairfax, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.